Alnylam Presents 18-Month P-III Study (APOLLO-B) Results of Patisiran for ATTR Amyloidosis with Cardiomyopathy at HFA 2023
Shots:
- The results from an interim analysis of exploratory data from an OLE period of the P-III study evaluating patisiran (0.3mg/kg, q3w) vs PBO in a ratio (1:1) in 360 adult patients
- The results showed a favorable effect on functional capacity (6-MWT), health status & QoL (KCCQ-OS) observed during the DB period were sustained with continued patisiran treatment during an OLE period
- Patients treated with patisiran were associated with the relative stability of cardiac stress (NT-proBNP) & cardiac injury (Troponin I) & also showed steadily rising cardiac biomarker levels up to 12mos. who received PBO in the DB period which then appeared to slow or stabilize after initiating patisiran in the OLE period. The safety profile was consistent with 12mos. results with no new safety concerns
Ref: Businesswire | Image: Alnylam
Related News:- Alnylam Expands its Collaboration with Medison Pharma to Commercialize RNAi Therapies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
